NCT01943292

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

A Phase I Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of VS-6063, a Focal Adhesion Kinase Inhibitor, in Japanese Subjects With Non-Hematologic Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Verastem, Inc. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies. The purpose of this study is to assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063).

Conditions

• Non Hematologic Cancers

Interventions

Type	Name	Description
DRUG	Defactinib

Timeline

• Start date: 2013-09-02
• Primary completion: 2014-06-09
• Completion: 2014-06-09
• First posted: 2013-09-16
• Last updated: 2017-03-09
• Results posted: 2015-11-20

Locations

1 site across 1 country: Japan